Excessive Daytime Sleepiness

A recent analysis reveals the safety profile of once-nightly sodium oxybate for narcolepsy, highlighting low discontinuation rates and common adverse events.

A new study evaluates the effectiveness and safety of once-nightly sodium oxybate for narcolepsy, aiming to enhance patient treatment experiences.

A phase 2 study shows samelisant significantly reduces excessive daytime sleepiness in narcolepsy, paving the way for further research and development.

Recent findings from an analysis showed that sodium oxybate significantly reduced narcolepsy symptoms, including cataplexy and excessive daytime sleepiness, among patients with the sleep disorder.

The phase 2, placebo-controlled, crossover trial will test whether 50 mg once daily lorundrostat may relieve the severity of upper airway obstruction and reduce nocturnal hypertension.

Over the 6-month treatment period, patients saw improvements in cataplexy frequency, excessive daytime sleepiness, cognition, and work productivity with AXS-12.